Relay Therapeutics (RLAY) Competitors $4.50 -0.34 (-7.02%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends RLAY vs. JANX, EWTX, XENE, MRUS, TWST, ACAD, MOR, VCEL, ZLAB, and SWTXShould you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Xenon Pharmaceuticals (XENE), Merus (MRUS), Twist Bioscience (TWST), ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), Vericel (VCEL), Zai Lab (ZLAB), and SpringWorks Therapeutics (SWTX). These companies are all part of the "pharmaceutical products" industry. Relay Therapeutics vs. Janux Therapeutics Edgewise Therapeutics Xenon Pharmaceuticals Merus Twist Bioscience ACADIA Pharmaceuticals MorphoSys Vericel Zai Lab SpringWorks Therapeutics Relay Therapeutics (NASDAQ:RLAY) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends. Which has better earnings and valuation, RLAY or JANX? Janux Therapeutics has higher revenue and earnings than Relay Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelay Therapeutics$10.01M75.28-$341.97M-$2.61-1.72Janux Therapeutics$13.05M239.75-$58.29M-$1.17-50.95 Which has more risk and volatility, RLAY or JANX? Relay Therapeutics has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 3.29, suggesting that its stock price is 229% more volatile than the S&P 500. Do analysts rate RLAY or JANX? Relay Therapeutics currently has a consensus price target of $20.50, suggesting a potential upside of 355.56%. Janux Therapeutics has a consensus price target of $89.90, suggesting a potential upside of 50.81%. Given Relay Therapeutics' higher probable upside, equities research analysts clearly believe Relay Therapeutics is more favorable than Janux Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relay Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor RLAY or JANX? Relay Therapeutics received 18 more outperform votes than Janux Therapeutics when rated by MarketBeat users. However, 70.18% of users gave Janux Therapeutics an outperform vote while only 69.05% of users gave Relay Therapeutics an outperform vote. CompanyUnderperformOutperformRelay TherapeuticsOutperform Votes5869.05% Underperform Votes2630.95% Janux TherapeuticsOutperform Votes4070.18% Underperform Votes1729.82% Is RLAY or JANX more profitable? Relay Therapeutics has a net margin of 0.00% compared to Janux Therapeutics' net margin of -463.91%. Janux Therapeutics' return on equity of -10.47% beat Relay Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Relay TherapeuticsN/A -45.75% -40.75% Janux Therapeutics -463.91%-10.47%-9.86% Do insiders & institutionals have more ownership in RLAY or JANX? 97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 4.3% of Relay Therapeutics shares are held by company insiders. Comparatively, 29.4% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media prefer RLAY or JANX? In the previous week, Relay Therapeutics had 6 more articles in the media than Janux Therapeutics. MarketBeat recorded 12 mentions for Relay Therapeutics and 6 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 0.64 beat Relay Therapeutics' score of 0.56 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryJanux Therapeutics beats Relay Therapeutics on 12 of the 18 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLAY vs. The Competition Export to ExcelMetricRelay TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$753.22M$2.98B$5.14B$9.31BDividend YieldN/A1.85%4.81%4.06%P/E Ratio-1.7247.03135.3117.54Price / Sales75.28420.231,215.74139.37Price / CashN/A182.1340.5837.95Price / Book0.763.924.884.92Net Income-$341.97M-$42.03M$118.89M$225.78M7 Day Performance-9.64%-3.37%16.99%-1.58%1 Month Performance-7.98%7.95%16.58%6.67%1 Year Performance-55.84%21.00%35.26%22.48% Relay Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLAYRelay Therapeutics2.368 of 5 stars$4.50-7.0%$20.50+355.6%-55.6%$753.22M$10.01M-1.72304JANXJanux Therapeutics3.5946 of 5 stars$62.03+1.5%$89.90+44.9%+474.8%$3.26B$13.05M-52.2330EWTXEdgewise Therapeutics2.8288 of 5 stars$33.86+22.6%$42.33+25.0%+313.9%$3.21BN/A-22.8560Analyst ForecastShort Interest ↓News CoverageGap UpHigh Trading VolumeXENEXenon Pharmaceuticals2.7658 of 5 stars$40.94+2.2%$56.90+39.0%-0.3%$3.12B$9.43M-14.20251MRUSMerus2.9299 of 5 stars$42.93+0.2%$85.64+99.5%+77.9%$2.94B$35.93M-10.8437TWSTTwist Bioscience2.8772 of 5 stars$48.66+2.4%$51.90+6.7%+39.8%$2.89B$312.97M-13.19990ACADACADIA Pharmaceuticals3.9246 of 5 stars$17.27+0.1%$25.60+48.2%-39.1%$2.87B$726.44M22.13510MORMorphoSys0.0797 of 5 stars$18.96+2.4%$14.33-24.4%N/A$2.86B$238.28M-5.45730VCELVericel0.903 of 5 stars$57.35-0.2%$59.71+4.1%+54.0%$2.83B$226.84M957.83300Positive NewsZLABZai Lab2.5215 of 5 stars$26.03-1.1%$55.00+111.3%-10.1%$2.83B$355.75M-9.512,175SWTXSpringWorks Therapeutics1.9318 of 5 stars$37.80-1.3%$69.50+83.9%+11.0%$2.81B$5.45M-9.87305Positive News Related Companies and Tools Related Companies JANX Alternatives EWTX Alternatives XENE Alternatives MRUS Alternatives TWST Alternatives ACAD Alternatives MOR Alternatives VCEL Alternatives ZLAB Alternatives SWTX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RLAY) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
